FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

Check this box if no longer subject	
to Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Crowley John F</u>					2. Issuer Name and Ticker or Trading Symbol AMICUS THERAPEUTICS, INC. [FOLD											tionship all app Direc	,				
l	ICUS THE	(First) (Middle) US THERAPEUTICS, INC. KET STREET				3. Date of Earliest Transaction (Month/Day/Year) 07/01/2022										X Officer (give title Other (specify below) Chairman & CEO					
(Street) PHILADELPHIA PA 19104 (City) (State) (Zip)					4. lf	4. If Amendment, Date of Original Filed (Month/Day/Year)									3. Indivine)	<i>'</i>					
		Table	I - N	lon-Deriva	tive	Secu	rities	Ac	quir	ed, D	Disp	posed c	of, or	Benefic	ially	Own	ed				
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye			Execution Da		n Date	n Date, T				4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and			nd 5) Secur Benef Owne		cially d Following	Form (D) or Indire	n: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership			
							(Code V		Am	nount	(A) or (D)	A) or D) Price		Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)		(Instr. 4)		
Common Stock 07/01/20				07/01/202	2	:			S ⁽¹⁾		1	1,346	D	\$10.78	24(2)	910,993			D		
Common Stock															64,895			I	By Trust		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if an	Deemed cution Date, y nth/Day/Year)		Transaction of Code (Instr. Derivative				Expiration Date (Month/Day/Year) Set Unit of the bod o				nount of curities derlying (Ir rivative curity (Instr. nd 4)		rice of ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	, G	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	de V (A) (D)				te ercisab	Expiration o		Amount or Number of Shares								

Explanation of Responses:

- 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- 2. This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from \$10.57 to \$10.97 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the reported transactions, Mr. Crowley also has approximately 522,000 options outstanding and exercisable at various strike prices.

/s/ Christian Formica, 07/06/2022 Attorney-in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.